NEW YORK (GenomeWeb) — Quidel said after the close of the market on Wednesday that third quarter revenues grew 14 percent to $46.8 million from $41.2 million in Q3 2014, beating the average analyst estimate of $43.5 million.

The increase was driven by sales of the firm's Sofia immunoassay products as well as other new products, which increased by 76 percent year-over-year to $16.6 million. Meanwhile, molecular revenues increased 52 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.